The effect of NSAIDs exposure on breast cancer risk in female patients with autoimmune diseases
| Autor: | Ting-Yi Wu, Ming-Feng Hou, Chih-Hsing Hung, Yu-Han Chang, Yu-Chih Lin, Yi-Ching Lin, Wei-Ju Yeh, Hsin-Yi Huang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male musculoskeletal diseases Cancer Research medicine.medical_specialty Databases Factual Epidemiology Taiwan Breast Neoplasms Piroxicam digestive system Autoimmune Diseases Young Adult 03 medical and health sciences 0302 clinical medicine Breast cancer Diclofenac Risk Factors Internal medicine medicine Humans Breast 030212 general & internal medicine Young adult skin and connective tissue diseases Aged Proportional Hazards Models Aged 80 and over Dose-Response Relationship Drug business.industry Proportional hazards model Incidence Incidence (epidemiology) Anti-Inflammatory Agents Non-Steroidal Hazard ratio Public Health Environmental and Occupational Health Middle Aged medicine.disease digestive system diseases Confidence interval Oncology 030220 oncology & carcinogenesis Female business Follow-Up Studies medicine.drug |
| Zdroj: | European Journal of Cancer Prevention. 28:428-434 |
| ISSN: | 0959-8278 |
| Popis: | Both breast cancer and autoimmune diseases (ADs) are predominant in women. NSAIDs are common medications for AD. Evidence on the association between NSAIDs use and breast cancer risk is controversial. We investigated the association between NSAIDs exposure and breast cancer risk in female patients with AD. AD patients older than 18 years of age were enrolled from Taiwan Longitudinal Health Insurance Database 2005. The NSAID users were defined as AD patients who had ever taken NSAIDs for at least 3 months between 2000 and 2009. All individuals were followed from the date of first diagnosis of AD to the end of 2013 to evaluate the risk of breast cancer. We estimated the adjusted hazard ratio (HR) using Cox proportional hazard regression after adjusting for age, comorbidities and medications. A total of 12 331 NSAID users and 12 331 non-NSAID users were included in this study after 1: 1 individual matching. The NSAID users were less likely to develop breast cancer than the non-NSAID users (adjusted HR: 0.37; 95% confidence interval: 0.27-0.50; P < 0.001), even if they used NSAIDs with low cumulative defined daily doses (adjusted HR: 0.42; 95% confidence interval: 0.34-0.53; P < 0.001). The incidence of new-onset breast cancer in NSAID users was significantly decreased in users taking selective cyclooxygenase 2 inhibitors, diclofenac, ibuprofen and piroxicam. Lower cumulative hazard rates were found in the AD patients who used NSAIDs (P < 0.001). NSAID exposure is associated with a decreased risk of breast cancer in female AD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|